Is early recurrence of hepatocellular carcinoma in HCV cirrhotic patients affected by treatment with direct‐acting antivirals? A prospective multicentre study

Abstract

Probability of HCC early recurrence in patients who had HCC previously cured remains high, despite HCV eradication by DAAs. Risk was comparable but not higher to that reported in literature in DAA-untreated patients. Previous HCC recurrence and tumour size can be used to stratify the risk of HCC early recurrence. Further studies are needed to assess impact of DAAs on late recurrence and mortality.